



NUUVERA AND APHRIA ANNOUNCE NEGOTIATIONS FOR AN OFFTAKE AGREEMENT

Toronto (January 11, 2018) - Nuuvera Inc. ("Nuuvera") (TSXV: NUU) and Aphria Inc. ("Aphria") (TSX: APH & US OTC QB: APHQF) announced today that they are in negotiations regarding an offtake agreement.

On January 8, 2018, Aphria announced that it had entered into a strategic relationship with Double Diamond Farms to provide Aphria with 120,000 kgs of annual cannabis production. Nuuvera announced today that it is in negotiations with Aphria regarding an offtake agreement for 60,000 kgs of such cannabis production which is expected to be available for sale in January 2019, pending Health Canada approvals. Further details will be provided upon the parties entering into a definitive agreement. There can be no assurance that a definitive offtake agreement will be executed.

For more information, please visit: www.nuuvera.com

-30-

For media inquiries only please contact:

Justin Burrows
Venture Communications
justin@venturecommunications.ca
1-416-276-7699

About Nuuvera

Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. Through its subsidiaries, ARA – Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its "letter to build" approval.

About Aphria

Aphria Inc., one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

For more information, visit www.Aphria.com.

Notice regarding forward-looking statements:



This release includes forward-looking statements regarding Nuuvera and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Nuuvera. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Nuuvera, including risks regarding the cannabis industry, failure to obtain regulatory approvals, economic factors, the equity markets generally and risks associated with growth and competition. Although Nuuvera has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made Nuuvera undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.